 |
424 Diseases |  |
809 Trials |
|
809 Trials |  |
14393 News |  |
| «12...109110111112113114115116117118119...235236» |
- Abraxane (albumin-bound paclitaxel) / BMS, Otsuka
CHEMOTHERAPY TOXICITY AND DOSE INTENSITY IN PATIENTS WITH PANCREATIC DUCTAL ADENOCARCINOMA AND GERMLINEBRCA1-2 PATHOGENIC VARIANTS (GBRCA1-2PV) ([VIRTUAL]) - Dec 31, 2021 - Abstract #AIOM2021AIOM_187;
Furthermore, apparently improved outcome was observed with platinum-based triplets or quadruplets. Table1.
- Abraxane (albumin-bound paclitaxel) / BMS, Otsuka
THE IMPACT OF FIRST-LINE CHEMOTHERAPY IN ELDERLY PATIENTS (PTS) WITH ADVANCED PANCREATIC CANCER (APC): A MONO-INSTITUTIONAL RETROSPECTIVE STUDY ([VIRTUAL]) - Dec 31, 2021 - Abstract #AIOM2021AIOM_184;
On the basis of our results, the baseline ECOG PS can be considered a prognostic factor for both PFS and OS. In conclusion, elderly pts should not be precluded from an active treatment and careful patient selection, mainly according to baseline ECOG PS, should guide treatment indication.
- Erbitux (cetuximab) / Eli Lilly, EMD Serono
SKIN TOXICITY MANAGEMENT IN LEFT-SIDED RAS AND BRAF WILD-TYPE METASTATIC COLORECTAL CANCER PATIENTS TREATED WITH FIRST-LINE ANTI-EGFR-BASED DOUBLET REGIMEN: A MULTICENTER STUDY ([VIRTUAL]) - Dec 31, 2021 - Abstract #AIOM2021AIOM_174;
Although recommended by international guidelines, a pre-emptive approach to the anti-EGFR-related skin toxicity in mCRC patients still appears less adopted in daily clinical practice compared to a reactive management. A wider reception and application of this indication is desirable to potentially improve quality of life of patients without impair continuity in antineoplastic therapy.
- Avastin (bevacizumab) / Roche
THE ROLE OF SITE OF METASTATIC RESECTION (MR) IN METASTATIC COLORECTAL CANCER (MCRC) PATIENTS (PTS): A MONO-INSTITUTIONAL COHORT STUDY ([VIRTUAL]) - Dec 31, 2021 - Abstract #AIOM2021AIOM_170;
A higher number of MR is associated to long-term survival and this could be explained with an accurate selection of pts that could benefit from multiple MR. A multidisciplinary approach is essential for the management of mCRC pts and surgery should be evaluated and performed independently of site of MR.
- 5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg.
MONOCYTES TO RED BLOOD CELLS RATIO (MRR): AN INNOVATIVE HAEMATOLOGIC PROGNOSTIC PARAMETER IN METASTATIC COLORECTAL CANCER PATIENTS TREATED WITH FOLFIRI-AFLIBERCEPT - A SUBGROUP ANALYSIS FROM THE DISTINCTIVE STUDY - A GISCAD TRIAL ([VIRTUAL]) - Dec 31, 2021 - Abstract #AIOM2021AIOM_169;
P=N/A
Our findings confirmed the prognostic role of some haematologic parameters and suggested an innovative and easy-to assess ratio in RAS wt mCRC pts receiving FOLFIRI-aflibercept in the second-line setting. This study was partially supported by Sanofi Genzyme.
- 5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg.
CIRCULATING PRO-ANGIOGENIC FACTORS DYNAMIC CHANGES DURING TREATMENT WITH FOLFIRI-AFLIBERCEPT: INTERIM ANALYSIS OF DISTINCTIVE STUDY - A GISCAD TRIAL ([VIRTUAL]) - Dec 31, 2021 - Abstract #AIOM2021AIOM_163;
P=N/A
Based on the results of our analysis, the change of pro-angiogenic factors levels during FOLFIRI-aflibercept might be a promising predictive factor for treatment efficacy. This study was partially supported by Sanofi Genzyme.
- 5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg.
POST-INDUCTION MANAGEMENT IN LEFT-SIDED RAS AND BRAF WILD-TYPE METASTATIC COLORECTAL CANCER PATIENTS TREATED WITH FIRST-LINE ANTI-EGFR-BASED DOUBLET REGIMENS: A MULTICENTER, “REAL-LIFE” STUDY ([VIRTUAL]) - Dec 31, 2021 - Abstract #AIOM2021AIOM_162;
Among these, 118 (33.2%), 66 (18.6%), and 11 (3.1%) received maintenance with 5-fluorouracil/leucovorin (5FU/LV)+anti-EGFR, anti-EGFR, and 5FU/LV, respectively, while 160 (45.1%) patients continued induction treatment (non-maintenance) until disease progression, unacceptable toxicity, patient decision or completion of planned treatment. Among treatment strategies following an anti-EGFR-based doublet first-line induction regimen in patients affected by left-sided RAS/BRAF wild-type mCRC treated in a “real-life” setting, 5FU/LV+anti-EGFR resulted the most adopted, effective and relatively safe regimen.
- Age-related safety and efficacy of perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin and docetaxel (FLOT) in elderly patients ([VIRTUAL]) - Dec 31, 2021 - Abstract #SIOG2021SIOG_18;
Fifty individuals (68.5%) completed preoperative chemotherapy, 65 (89%) underwent surgery, and 42 out of the 54 (78%) that were assigned to the postoperative phase received four cycles of chemotherapy. No statistically significant differences across age groups were found in R0 ressection and pathological complete response (pCR) rates.
- oxaliplatin / Generic mfg.
Tolerability and feasibility of oxaliplatin-containing adjuvant chemotherapy for elderly patients with colorectal cancer ([VIRTUAL]) - Dec 31, 2021 - Abstract #SIOG2021SIOG_16;
Sixteen patients received CAPOX and 17 patients received FOLFOX. The median age was 74.5 and 74 years, male was 56% and 53%, and performance status of 0/1 was 62%/38% and 76%/24%, respectively.
- || Avastin (bevacizumab) / Roche, Erbitux (cetuximab) / Eli Lilly, EMD Serono
Review, Journal, Combination therapy: Triplet chemotherapy in combination with anti-EGFR agents for the treatment of metastatic colorectal cancer: Current evidence, advances, and future perspectives. (Pubmed Central) - Dec 31, 2021
While the recommended dosing schedule for the triplet chemotherapy regimen with 5-fluorouracil, oxaliplatin and irinotecan (FOLFOXIRI) in combination with bevacizumab is well established, the optimal dosing of FOLFOXIRI in combination with anti-EGFR agents is unknown...Trials of anti-EGFR agents in combination with FOLFOXIRI have also shown promising results. In this review, we summarize the emerging evidence regarding the safety and efficacy of anti-EGFR agents in combination with triplet chemotherapy regimens and discuss the potential for this combination as a future treatment option for patients with RAS-wild-type mCRC.
- || Abraxane (albumin-bound paclitaxel) / BMS, Otsuka
Clinical, Journal: A single-institutional analysis of racial disparities in clinicopathologic characteristics, treatment selections, and outcomes in advanced-stage pancreatic cancer patients. (Pubmed Central) - Dec 30, 2021
Fifty-five-point-seven percent of patients received gemcitabine-based therapy vs. 36.6% received fluorouracil (5-FU) based therapy, specifically 26.1% received FOLFIRINOX and 43.7% received gemcitabine/nab-paclitaxel...There were no OS differences between AA vs. Whites nor Other vs. Whites (HR 1.12, P=0.769 and HR 0.8, P=0.763, respectively). In this series of advanced PDA patients treated with contemporary chemotherapy, AA and White patients had comparable outcomes, but Asians had worse OS than White patients.
- |||| 5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg., Opdivo (nivolumab) / Ono Pharma, BMS
Clinical: I sure can but I know nothing about GI oncology other than FOLFOX and FOLFIRI .. was there any update in GI oncology😉😂 Adjuvant Nivolumab in Resected Esophageal or Gastroesophageal Junction Cancer https://t.co/WLmGOnBQkl (Twitter) - Dec 30, 2021
- || 5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg.
Clinical, Journal: Feasibility of intracerebrally administering multiple doses of genetically modified neural stem cells to locally produce chemotherapy in glioma patients. (Pubmed Central) - Dec 30, 2021
In a prior first-in-human study we demonstrated that a single dose of intracerebrally administered allogeneic NSCs, which were retrovirally transduced to express cytosine deaminase (CD), tracked to glioma sites and converted oral 5-fluorocytosine (5-FC) to 5-fluorouracil (5-FU)...CD-NSCs were given every 2 weeks using an indwelling brain catheter, followed each time by a 7-d course of oral 5-FC (and leucovorin in the final patient cohort)...There were no clinical signs of immunogenicity, and only three patients developed anti-NSC antibodies. Our results suggest intracerebral administration of serial doses of CD-NSCs is safe and feasible and identified a recommended dose for phase II testing of 150 × 10 CD-NSCs.
- || 5-fluorouracil / Generic mfg., oxaliplatin / Generic mfg., leucovorin calcium / Generic mfg.
Clinical, P2 data, Journal: Hepatectomy Followed by mFOLFOX6 Versus Hepatectomy Alone for Liver-Only Metastatic Colorectal Cancer (JCOG0603): A Phase II or III Randomized Controlled Trial. (Pubmed Central) - Dec 30, 2021
Adjuvant chemotherapy with mFOLFOX6 improves DFS among patients treated with hepatectomy for CRC liver metastasis. It remains unclear whether chemotherapy improves OS.
- |||||||||| New P2/3 trial: CIRCULATE-US: Colon Adjuvant Chemotherapy Based on Evaluation of Residual Disease (clinicaltrials.gov) - Dec 29, 2021
P2/3, N=1912, Not yet recruiting, Sponsor: NRG Oncology
- || 5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg.
Very important message: the preventive management of FOLFOXIRI toxicity (Twitter) - Dec 29, 2021
- | 5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg., irinotecan / Generic mfg.
Review, Journal: Modulation of pancreatic cancer cell sensitivity to FOLFIRINOX through microRNA-mediated regulation of DNA damage. (Pubmed Central) - Dec 29, 2021
FOLFIRINOX, a combination of chemotherapy drugs (Fluorouracil, Oxaliplatin, Irinotecan -FOI), provides the best clinical benefit in pancreatic ductal adenocarcinoma (PDAC) patients...We validate these findings in an in vivo model with MIR1307 disruption. In a pilot cohort of PDAC patients undergoing FOLFIRONX chemotherapy, circulating MIR1307 correlates with clinical outcome.
- | oxaliplatin / Generic mfg., albumin-bound paclitaxel / Generic mfg., gemcitabine / Generic mfg.
Trial initiation date, Combination therapy, Metastases: TCOG T5221: A Phase II Randomized Study of Gemcitabine and Nab-paclitaxel in Combination With S- 1/LV (GASL) or Oxaliplatin (GAP) as First-line Treatment for Metastatic Pancreatic Cancer (clinicaltrials.gov) - Dec 28, 2021
P2, N=86, Not yet recruiting, Sponsor: National Health Research Institutes, Taiwan
In a pilot cohort of PDAC patients undergoing FOLFIRONX chemotherapy, circulating MIR1307 correlates with clinical outcome. Initiation date: Oct 2021 --> Dec 2021
- | Zepsun (donafenib) / Suzhou Zelgen
New P2/3 trial: Neo-TACE: Neoadjuvant HAIC of TACE Plus Donafenib in BCLC B Stage HCC: a Multi-center Randomized Controlled Trial. (clinicaltrials.gov) - Dec 28, 2021
P2/3, N=156, Not yet recruiting, Sponsor: Peking University
- | leucovorin calcium / Generic mfg.
Preclinical, Journal: Effects of Folinic Acid Administration on Lower Limb Ischemia/Reperfusion Injury in Rats. (Pubmed Central) - Dec 27, 2021
Following 3 h of lower limb ischemia, FA minimizes the increase of CK and LDH, as well as local edema and leukocyte infiltration, allowing a faster recovery of limb functionality. Therefore, it could be considered as a prophylactic treatment when tourniquet is used in clinics.
- || 5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg.
Clinical, Journal: Pathological complete response after neoadjuvant chemotherapy with FOLFOX for locally advanced sigmoid colon cancer with diverticulitis: A case report. (Pubmed Central) - Dec 27, 2021
We present a rare case of pathological complete after neoadjuvant chemotherapy with FOLFOX for locally advanced colon cancer in the sigmoid colon complicated by diverticulitis. Our experience may be valuable in determining the optimal treatment strategy for LACC complicated by diverticulitis.
- | Bylantra (devimistat) / Cornerstone Pharma
Trial completion date, Combination therapy, Metastases: CPI-613 and Combination Chemotherapy in Treating Patients With Metastatic Pancreatic Cancer (clinicaltrials.gov) - Dec 27, 2021
P1, N=21, Active, not recruiting, Sponsor: Wake Forest University Health Sciences
Our experience may be valuable in determining the optimal treatment strategy for LACC complicated by diverticulitis. Trial completion date: Dec 2021 --> Jun 2022
- | Abraxane (albumin-bound paclitaxel) / BMS, Otsuka
Journal: Delta HU is a potential marker to predict chemotherapy response for unresectable pancreatic ductal adenocarcinoma. (Pubmed Central) - Dec 25, 2021
Higher delta HU was associated with better survival for patients receiving mFOLFIRINOX rather than AG. The delta HU was positively correlated with stroma MVD, explaining the relationship between delta HU and prognosis.
- || 5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg., gemcitabine / Generic mfg.
Biomarker, Clinical, Journal: Tailored adjuvant gemcitabine versus 5-fluorouracil/folinic acid based on hENT1 immunohistochemical staining in resected pancreatic ductal adenocarcinoma: A biomarker stratified prospective trial. (Pubmed Central) - Dec 25, 2021
P=N/A
The delta HU was positively correlated with stroma MVD, explaining the relationship between delta HU and prognosis. Tailored adjuvant chemotherapy based on hENT1 staining provides excellent clinical outcomes among patients with resected PDA.
- || 5-fluorouracil / Generic mfg., oxaliplatin / Generic mfg., leucovorin calcium / Generic mfg.
Clinical, Journal: Critical reappraisal of neoadjuvant concurrent chemoradiotherapy for treatment of locally advanced colon cancer. (Pubmed Central) - Dec 25, 2021
Pathologic N downstaging was an independent prognostic factor for patients' overall survival. However, a large prospective, randomized control study is required to confirm the current results.
- || 5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg.
I’m waiting until after Christmas to rechallange FOLFIRI… I hear you can get a better deal. (Twitter) - Dec 23, 2021
- ||| 5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg., Erbitux (cetuximab) / Eli Lilly, EMD Serono
Clinical: First line FOLFOX cetuximab X3 course Progressive Disease (PD) - While taking cetuximab, the F1cDX(tissue) had not yet been reported. All RAS and MSı status were examined by PCR only and negative. (Twitter) - Dec 23, 2021
- || cisplatin / Generic mfg.
P1 data, Journal: PIPAC for the Treatment of Gynecologic and Gastrointestinal Peritoneal Metastases: Technical and Logistic Considerations of a Phase 1 Trial. (Pubmed Central) - Dec 23, 2021
The PIPAC treatment is a feasible, minimally invasive approach that permits IP delivery of chemotherapy. Once completed, the ongoing phase 1 trial will help to provide safety and initial efficacy data.
- || Review, Journal: Proton pump inhibitors and colorectal cancer: A systematic review. (Pubmed Central) - Dec 23, 2021
This review identifies that different PPI agents may have differential effects on CRC treatment, with practical implications. Prospective studies are warranted to delineate this relationship and assess the role of individual PPI agents.
- |||| 5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg.
📣analysis of TRIBE&TRIBE2 on impact of neutropenia @ESMO_Open 📉 AEs over time is crucial in trials ✔️FOLFOXIRI/bev: higher risk G3-4 neutropenia & FN 🔀closer monitoring in first 2 mos ⚠️prophylactic GCSF for older& females.@IlBuonRossini @FilippoPietran4 @ChiaraCrem1 #crcsm (Twitter) - Dec 22, 2021
- ||| Avastin (bevacizumab) / Roche, Erbitux (cetuximab) / Eli Lilly, EMD Serono
Clinical, P3 data, Journal, Adverse events: Early weight loss is an independent risk factor for shorter survival and increased side effects in patients with metastatic colorectal cancer undergoing first-line treatment within the randomized phase III trial FIRE-3 (AIO KRK-0306). (Pubmed Central) - Dec 22, 2021
Patients exhibiting EWL had worse survival and higher frequencies of adverse events. Early preventative measures targeted at weight maintenance should be evaluated, especially in elderly patients being at highest risk of EWL.
- || oxaliplatin / Generic mfg.
Clinical, Journal: Survival outcomes associated with completion of adjuvant oxaliplatin-based chemotherapy for stage III colon cancer: a national population-based study. (Pubmed Central) - Dec 22, 2021
Competing risk regression analysis for 3-year cancer-specific mortality was performed according to completion of <6, 6-11, or 12 5-fluoropyrimidine and oxaliplatin (FOLFOX) cycles, or <4, 4-7, or 8 capecitabine and oxaliplatin (CAPOX) cycles, adjusted for patient, tumour and hospital-level characteristics...Poor prognostic factors may have affected findings, however, patients completing <50% of cycles had poor outcomes. Clinicians may wish to facilitate completion with treatment modification in those able to tolerate it.
- || 5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg.
Clinical, Journal: Clinical Impact of the Administration of FOLFIRINOX Beyond Six Months in Advanced Pancreatic Adenocarcinoma: A Cohort Study. (Pubmed Central) - Dec 21, 2021
The general incidence of hematologic and neurologic toxicity was higher than the ones reported in the literature. Conclusion The study revealed that patients benefit from the administration of FOLFIRINOX for more than six months, but that the administration of full dose and the maintaining dose intensity does not necessarily favor the patient.
- ||| izalontamab (SI-B001) / Biokin Pharma
Enrollment open, Combination therapy, Metastases: SI-B001 as a Single Agent or in Combination With Chemotherapy in the Treatment of Digestive System Malignancies (clinicaltrials.gov) - Dec 21, 2021
P2, N=120, Recruiting, Sponsor: Sichuan Baili Pharmaceutical Co., Ltd.
Conclusion The study revealed that patients benefit from the administration of FOLFIRINOX for more than six months, but that the administration of full dose and the maintaining dose intensity does not necessarily favor the patient. Not yet recruiting --> Recruiting
- || Enrollment change, Trial primary completion date: A Study Evaluating the Safety and Efficacy of Targeted Therapies in Subpopulations of Patients With Metastatic Colorectal Cancer (INTRINSIC) (clinicaltrials.gov) - Dec 20, 2021
P1, N=220, Recruiting, Sponsor: Hoffmann-La Roche
Not yet recruiting --> Recruiting N=80 --> 220 | Trial primary completion date: Jul 2023 --> May 2024
- |||| Clinical: Sequential first-line treatment with nab-paclitaxel/gemcitabine and FOLFIRINOX in metastatic pancreatic adenocarcinoma: GABRINOX phase Ib-II controlled clinical trial https://t.co/YC8TKEwl2Z (Twitter) - Dec 19, 2021
- || Avastin (bevacizumab) / Roche
Clinical, Journal: Multiple stage IV colorectal cancers in a patient who received multidisciplinary treatment, including chemotherapy and Japanese Kampo medicine: A case report. (Pubmed Central) - Dec 18, 2021
The patient recovered uneventfully, and Kampo medicine consisting of Ninjin'yoeito was administered for postoperative weakness. Administration of adjuvant chemotherapy in this patient led to a near complete response that has been maintained without recurrence for 2 years and 8 months without reduced quality of life.
- || irinotecan / Generic mfg.
Clinical, Observational data, Journal: Outcome of neoadjuvant treatment for pancreatic cancer in elderly patients: comparative, observational cohort study. (Pubmed Central) - Dec 18, 2021
The safety and efficacy of multiagent chemotherapy in patients aged 75 years or over were similar to those in younger patients. Modern multiagent regimens could be a safe and viable treatment option for clinically fit patients aged at least 75 years.
- || 5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg., irinotecan / Generic mfg.
Biomarker, Clinical, Journal: p130Cas Is Correlated with EREG Expression and a Prognostic Factor Depending on Colorectal Cancer Stage and Localization Reducing FOLFIRI Efficacy. (Pubmed Central) - Dec 18, 2021
p130Cas expression was associated with poor survival in right-sided, stage I/II, MSS (microsatellite stable), or BRAF-mutated CRC. In summary, p130Cas represents a prognostic factor and potential therapeutic target in CRC.
- || leucovorin calcium / Generic mfg., erythromycin / Generic mfg.
Clinical, Journal: Methotrexate-induced toxidermia and pancytopenia in a patient with ectopic pregnancy: a case report. (Pubmed Central) - Dec 18, 2021
Our case is mainly distinguished by the lack of use of granulocyte growth factors and folinic acid. In the event of severe reactions to methotrexate, the management should be multidisciplinary and as much as possible within an intensive care unit.
- 5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg.
TOTAL PANCREATECTOMY, SPLENECTOMY, AND REMNANT GASTRECTOMY FOR INVASIVE IPMN AFTER PRIOR ROUX-EN-Y GASTRIC BYPASS ([VIRTUAL]) - Dec 17, 2021 - Abstract #APCM2021APCM_167;
Resection of the gastric remnant is preferable with RYGB anatomy due to avoidance of the enteric anastomosis. Due to biliary obstruction, coagulopathy is common and should be corrected preoperatively, with continued postoperative monitoring and correction.
- 5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg., gemcitabine / Generic mfg.
THE FATE OF RESECTABLE PANCREATIC ADENOCARCINOMA FOLLOWING NEOADJUVANT CHEMOTHERAPY ([VIRTUAL]) - Dec 17, 2021 - Abstract #APCM2021APCM_158;
Most patients with resectable pancreatic cancer are resected after neoadjuvant chemotherapy, but a subset will develop local or distant progression. Further studies will be needed to determine which patients will progress locally and may benefit from an upfront surgical approach.
- Abraxane (albumin-bound paclitaxel) / BMS, Otsuka
COMBINED THERAPY AND ISCHEMIA PRECONDITIONING TO ACHIEVE SAFE AND ONCOLOGICALLY COMPLETE RESECTION FOR LOCALLY ADVANCED PANCREATIC CANCER ([VIRTUAL]) - Dec 17, 2021 - Abstract #APCM2021APCM_155;
Based on this early experience, we find that pre-operative ischemia preconditioning is feasible and allows for safe, margin negative resection of select patients with LAPC and suitable anatomy. Larger analyses are necessary to confirm the findings of this study.
- irinotecan / Generic mfg.
THE CURRENT MANAGEMENT OF AMPULLARY CANCER: A SURVEY AMONG HEALTHCARE WORKERS WORLDWIDE ([VIRTUAL]) - Dec 17, 2021 - Abstract #APCM2021APCM_151;
This international survey study highlights the worldwide variation in the management of patients diagnosed with ampullary cancer, especially regarding neoadjuvant and/or adjuvant therapy. Consensus is reached that more data, including international registries and randomized controlled trials are needed to develop evidence-based guidelines for a more standardized surgical, and oncological management.
- 5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg., gemcitabine / Generic mfg.
THE IMPACT OF MULTI-AGENT CHEMOTHERAPY IN PANCREATIC ADENOCARCINOMA: A POPULATIONBASED STUDY UTILIZING THE SEER DATABASE ([VIRTUAL]) - Dec 17, 2021 - Abstract #APCM2021APCM_146;
This increase can be attributed due to advancements in improved chemotherapeutic agents including a global shift towards multi-agent chemotherapy. This occurs despite any paradigm shifting experimental improvements in cancer care in recent years.
- 5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg., gemcitabine / Generic mfg.
CA19-9 RESPONSE TO 1ST-LINE NEOADJUVANT FOLFIRINOX AND 2ND-LINE GEMCITABINE-BASED CHEMOTHERAPY IN PATIENTS WITH OPERABLE PANCREATIC CANCER ([VIRTUAL]) - Dec 17, 2021 - Abstract #APCM2021APCM_122;
Longitudinal monitoring of CA19-9 during neoadjuvant therapy may help maximize treatment response prior to surgery. Differences in chemotherapeutic susceptibility may be related to cancer subtype and are being investigated in our clinical trials of adaptive neoadjuvant therapy.
- 5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg.
ARTIFICIAL INTELLIGENCE-BASED SEGMENTATION OF RESIDUAL TUMOR IN PANCREATIC CANCER AFTER NEOADJUVANT TREATMENT ([VIRTUAL]) - Dec 17, 2021 - Abstract #APCM2021APCM_121;
This study shows that artificial intelligence techniques may be suited for this task given the promising Dice (F1) score. This algorithm could be developed into a tool to assess NAT response and guide the choice for adjuvant treatment.
- cisplatin / Generic mfg.
ONCOLOGIC OUTCOMES AFTER NEOADJUVANT SYSTEMIC THERAPIES IN PANCREATIC NEUROENDOCRINE TUMORS ([VIRTUAL]) - Dec 17, 2021 - Abstract #APCM2021APCM_116;
Neoadjuvant therapy is particularly attractive in those with liver metastases and a primary tumor in the pancreatic head where surgery warrants a biliary enteric anastomosis. This small experience provides a signal for improved overall survival after neoadjuvant therapy followed by surgery, despite a significant tumor burden at diagnosis.
- cisplatin / Generic mfg., paclitaxel / Generic mfg., irinotecan / Generic mfg.
DOES RACE AFFECT THE LONG-TERM SURVIVAL BENEFIT OF SYSTEMIC THERAPY IN PANCREATIC ADENOCARCINOMA? ([VIRTUAL]) - Dec 17, 2021 - Abstract #APCM2021APCM_103;
In our limited population, systemic therapy was more effective in White patients than Black patients. These findings may indicate differences in tumor biology between races.
- 5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg., gemcitabine / Generic mfg.
MARGIN STERILIZATION WITH STEREOTACTIC BODY RADIOTHERAPY IN LOCALIZED PANCREATIC ADENOCARCINOMA IMPROVES LOCAL CONTROL ([VIRTUAL]) - Dec 17, 2021 - Abstract #APCM2021APCM_85;
Patients who underwent resection experienced significantly improved survival and local control. However, despite aggressive local therapy with SBRT and resection, local failure remained not insignificant, highlighting opportunity to continue to refine radiation therapy for this disease.